Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Long Covid patients suffer from chronic symptoms such as fatigue or shortness of breath. As researchers have discovered, this is to some extent due to a part of our immune system called the complement ...

Increasing evidence supports associations between cognitive function and autoimmune disorders, yet the underlying genetic mechanisms remain unclear. Using large-scale ...

Changes to serum proteins could be behind the debilitating condition known as long COVID. The findings, published in the journal Science, could pave the way for diagnosing and treating the disease.

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...